Walter Elisei

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Journal: Advances in therapy

Published: February 11, 2026

An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients.

An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients.

Journal: Therapeutic advances in gastroenterology

Published: January 22, 2026

The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study.

The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study.

Journal: Techniques in coloproctology

Published: January 16, 2026

Analysis of possible baseline and treatment-course factors associated with non-remission in patients with Crohn's disease treated with ustekinumab: a retrospective real-life analysis.

Analysis of possible baseline and treatment-course factors associated with non-remission in patients with Crohn's disease treated with ustekinumab: a retrospective real-life analysis.

Journal: Pharmacological reports : PR

Published: December 15, 2025

Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis.

Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis.

Journal: Clinical pharmacology and therapeutics

Published: November 28, 2025

Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis.

Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis.

Journal: Journal of clinical medicine

Published: September 26, 2025

Impact of biosimilars on the costs of advanced therapies for inflammatory bowel diseases: a population-based study in Italy.

Impact of biosimilars on the costs of advanced therapies for inflammatory bowel diseases: a population-based study in Italy.

Journal: European journal of gastroenterology & hepatology

Published: September 10, 2025

Global guidelines on diverticular disease of the colon: the Fiesole Consensus report.

Global guidelines on diverticular disease of the colon: the Fiesole Consensus report.

Journal: Gut

Published: September 09, 2025

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Journal: Journal of clinical medicine

Published: August 27, 2025

Lactobacillus Paracasei CNCM I 1572 is Better than Placebo in Preventing Acute Diverticulitis Occurrence (Revised Manuscript 661a120f-b910-4133-ab7e-4bd3e1713c96).

Lactobacillus Paracasei CNCM I 1572 is Better than Placebo in Preventing Acute Diverticulitis Occurrence (Revised Manuscript 661a120f-b910-4133-ab7e-4bd3e1713c96).

Journal: Probiotics and antimicrobial proteins

Published: July 30, 2025

Showing 1-12 of 114

Last Updated: 09/26/2026